Efficacy and safety of setipiprant in seasonal allergic rhinitis: results from Phase 2 and Phase 3 randomized, double-blind, placebo- and active-referenced studies

摘要

Background Antagonism of chemoattractant receptor-homologous molecule on T-helper type-2 cells (CRTH2), a G-protein coupled receptor for prostaglandin D2, could be beneficial for treating allergic disorders. We present findings on the efficacy and safety/tolerability of a CRTH2 antagonist (setipiprant) in participants with seasonal allergic rhinitis (AR) in a real-life setting over 2?weeks. Methods A Phase 2 trial and a Phase 3 trial were conducted at seven centers in Texas, USA during the Mountain Cedar pollen season. Both were prospective, randomized, double-blind, placebo- and active-referenced (cetirizine) studies. The Phase 2 trial assessed setipiprant 100–1000?mg b.i.d. and 1000?mg o.d. versus placebo in adult and elderly participants. The Phase 3 trial assessed setipiprant 1000?mg b.i.d. in adolescent, adult, and elderly participants. Efficacy was assessed using daytime nasal symptom scores (DNSS), night-time nasal symptom scores (NNSS) and daytime eye symptom scores (DESS). Results 579 participants were randomized in the Phase 2 trial (mean age 41.6–43.4?years); 630 were randomized in the Phase 3 trial (mean age 37.5–40.7?years). A statistically significant, dose-related improvement in mean change from baseline DNSS was observed over 2?weeks with setipiprant 1000?mg b.i.d. versus placebo in the Phase 2 trial (?0.15 [95% CI ?0.29, ?0.01]; p?=?0.030). Setipiprant 1000?mg b.i.d. had no significant effect on this endpoint in the Phase 3 trial (?0.02 [95% CI ?0.12, 0.07]; p?=?0.652). Total and individual NNSS and DESS symptom scores were significantly improved with setipiprant 1000?mg b.i.d. versus placebo in the Phase 2 but not the Phase 3 trial. Setipiprant showed a favorable safety/tolerability profile. Conclusions The Phase 2 trial was the first large clinical study to assess a CRTH2 antagonist in seasonal AR in a real-life setting. Setipiprant dose-related efficacy in the Phase 2 trial was not confirmed during Phase 3. Setipiprant was well tolerated in both studies. Trial registration NCT01241214 and NCT01484119